PRIME: 5 years' experience

Human medicines European public assessment report (EPAR): Pavblu, aflibercept, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Date of authorisation: 20/03/2007, Revision: 34, Status: Authorised

Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 May 2025

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 September 2025, 14:00 (CEST) to 18 September 2025, 15:00 (CEST)

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 October 2025, 14:00 (CEST) to 14 October 2025, 15:00 (CEST)

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 14:00 (CET) to 18 December 2025, 15:00 (CET)

Q&A clinic on Substance, Organisation, Referentials Management Services, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 8 September 2025, 11:00 (CEST) to 8 September 2025, 12:00 (CEST)